US research roundup: Eli Lilly, General Dynamics, S&P Global
SPY•Analysts raised Eli Lilly’s price target to $1,570 from $1,400, General Dynamics’ to $455 from $440, and S&P Global’s to $572 from $553. The roundup covers rating and price-target changes for numerous other US-listed companies.
1. Selected target changes
Berenberg raised its Eli Lilly target to $1,570 from $1,400, Jefferies raised its General Dynamics target to $455 from $440, and Barclays raised its S&P Global target to $572 from $553. The roundup also lists analyst actions across dozens of other US-listed companies, including target increases and cuts.
